ReviewWorld journal of gastroenterology2006
Emerging therapies in gastrointestinal cancers.
Review in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Role of cancer stem cells in age-related rise in colorectal cancer.World journal of gastrointestinal pathophysiology · 2015Article
- Cetuximab alleviates neuropathic pain despite tumour progression.BMJ case reports · 2012Article
- EGFR regulation of colon cancer stem-like cells during aging and in response to the colonic carcinogen dimethylhydrazine.American journal of physiology. Gastrointestinal and liver physiology · 2012Article
- Regulation of colon cancer recurrence and development of therapeutic strategies.World journal of gastrointestinal pathophysiology · 2012Article
- EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.Current protein & peptide science · 2010Review
- EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?Current drug targets · 2010Review
- ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.Molecular cancer therapeutics · 2010Article
- Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX.Translational oncology · 2009Article
- Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice.Gastroenterology · 2009Article
- Age-related increase in colorectal cancer stem cells in macroscopically normal mucosa of patients with adenomas: a risk factor for colon cancer.Biochemical and biophysical research communications · 2009Article
- Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.World journal of gastroenterology · 2008Review
- JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?World journal of gastroenterology · 2007Review
- Informed Consent among Clinical Trial Participants with Different Cancer Diagnoses.AJOB empirical bioethicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Members of the receptor tyrosine kinase family, that include EGFR, ErbB-2/HER-2, ErbB-3/HER-3 and ErbB-4/HER-4, are frequently implicated in experimental models of epithelial cell neoplasia as well as in human cancers. Therefore, interference with the activation of these growth factor receptors represents a promising strategy for development of novel and selective anticancer therapies. Indeed, a number of inhibitors that target either EGFR or HER-2, with the exception of a few that target both; have been developed for treatment of epithelial cancers. Since most solid tumors express different ErbB receptors and/or their ligands, identification of inhibitor(s), targeting multiple EGFR family members may provide a therapeutic benefit to a broader patient population. Here we describe the significance of an ErbB family of receptors in epithelial cancers, and summarize different available therapeutics targeting these receptors. It also emphasizes the need to develop pan-ErbB inhibitors and discusses EGF-Receptor Related Protein, a recently isolated negative regulator of EGFR as a potential pan-ErbB therapeutic for a wide variety of epithelial cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.